Venus Remedies has established pre-clinical proof of concept for its Drug-Protein-Polymer-Conjugate (DPPC). DPPC concept is a novel, patent protected technology, which will help in alleviating cancer specific and selective targeting of tumor cells.
The escalating prevalence of cancers of all kinds and the ever rising unmet need in the field of cancer treatment has made Venus to tap a huge market potential in the first year of the DPPC’s launch itself. This technology would bring revolution to the existing target anti-cancer therapies. The company is all geared up to commercially launch this novel triple conjugate therapy hopefully by next 2-3 years.
The company is also contributing successfully in the oncology segment across the globe through its wide array of key products, which includes Docetaxel, Paclitaxel, Gemcitabine, Oxaliplatin, Irinotecan and Topotecan. The company is also focusing on the anti-infective segment which is posing a threat to the mankind worldwide. Venus Medicine Research Centre (VMRC) is putting great efforts to come out with revolutionary drugs to eradicate these deadly infections.
